title: Weight loss in obese Mexican Americans treated for 1-year with orlistat and lifestyle modification.
abstract: OBJECTIVE
  To evaluate the effectiveness of a culturally appropriate lifestyle intervention combined with orlistat in producing weight loss with obese Mexican-American women.
  
  
  METHODS
  Mexican-American women (N=108), aged 21-65 y, with a body mass index (BMI) > or =27 kg/m(2) were randomized to 1 y of treatment with orlistat and a culturally tailored lifestyle modification intervention (OLM; n=56) or a wait-list control group (WLC; n=52).
  
  
  METHODS
  A randomized, controlled, open-label 12-month study. Orlistat was dosed at 120 mg, three times per day. The OLM intervention included behavior modification, a low-fat (< or =30% of total daily calories) diet, and moderate physical activity (> or =150 min/week).
  
  
  METHODS
  Primary outcomes included changes in body weight (kg), BMI, waist circumference, blood pressure, glucose, and lipids.
  
  
  RESULTS
  A total of 72 (37 OLM, 35 WLC) and 66 participants (32 OLM, 34 WLC) completed the 6- and 12-month follow-ups, respectively. Repeated-measures ANOVA demonstrated a significant time x treatment interaction (Wilks' lambda=12.61; P<0.001), indicating that OLM-treated patients achieved significant weight loss relative to the WLC group during the study (mean percentage weight loss+/-s.e.m.; -8.1%+/-1.2 vs -1.6%+/-0.7 at 6 months and -8.8%+/-1.5 vs -0.2%+/-1.0 at 12 months, respectively). OLM-treated patients also experienced significant reductions in waist circumference, low-density-lipoprotein, and total cholesterol.
  
  
  CONCLUSIONS
  This study demonstrates the effectiveness of an intervention combining orlistat and lifestyle modification with Mexican-American women, a population with substantial risk for obesity.
authors.affiliation: Mid America Heart Institute and University of Missouri-Kansas City, Kansas City, MO 64110, USA. postonwa@umkc.edu
authors.forename: W S Carlos
authors.initials: WS
authors.lastname: Poston
authors.forename: R S
authors.initials: RS
authors.lastname: Reeves
authors.forename: C K
authors.initials: CK
authors.lastname: Haddock
authors.forename: S
authors.initials: S
authors.lastname: Stormer
authors.forename: A
authors.initials: A
authors.lastname: Balasubramanyam
authors.forename: O
authors.initials: O
authors.lastname: Satterwhite
authors.forename: J E
authors.initials: JE
authors.lastname: Taylor
authors.forename: J P
authors.initials: JP
authors.lastname: Foreyt
mesh_terms: D000328:Adult; D000368:Aged; D019440:Anti-Obesity Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001521:Behavior Therapy; D002318:Cardiovascular Diseases / Q000209:etiology; D003131:Combined Modality Therapy; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007783:Lactones / Q000009:adverse effects / Q000627:therapeutic use*; D008019:Life Style; D008049:Lipase / Q000037:antagonists & inhibitors; D017058:Mexican Americans; D008875:Middle Aged; D009765:Obesity / Q000178:diet therapy / Q000208:ethnology / Q000628:therapy*; D000077403:Orlistat; D012307:Risk Factors; D016896:Treatment Outcome; D016312:Treatment Refusal; D015431:Weight Loss
chemical_list: D019440:Anti-Obesity Agents; D004791:Enzyme Inhibitors; D007783:Lactones; D000077403:Orlistat; D008049:Lipase